Literature DB >> 2525590

CR1, the C3b receptor, mediates binding of infective Leishmania major metacyclic promastigotes to human macrophages.

R P Da Silva1, B F Hall, K A Joiner, D L Sacks.   

Abstract

The role of complement receptors on monocyte derived human macrophages in phagocytosis of infective (MP) and noninfective (LP) developmental stages of Leishmania major promastigotes was studied. We compared binding of these specific developmental stages to MO after preincubation in fresh or heat-inactivated serum. Although LP do not require fresh serum for attachment, MP were dependent on serum C opsonization for entry. Inhibition of CR1 substantially abolished binding of the infective MP. In contrast, inhibition of iC3bR (CR3 and p150,95) had no effect on MP binding. Inhibition of both iC3bR, however, did block binding of nonopsonized LP. Attachment of LP to CR3 was blocked by fluid phase addition of mAb OKM1 and M1/70, which inhibit complement-independent binding to CR3, but not by mAb OKM10 which inhibits iC3b binding to this receptor. After fresh serum pretreatment of LP, however, only simultaneous inhibition of CR3 and CR1 effectively blocked their attachment. Addition of mannan did not inhibit attachment of either promastigote stage. Both opsonized and nonopsonized LP trigger a respiratory burst in MO, possibly via the C independent site in CR3, whereas the CR1-mediated uptake of MP does not generate a respiratory burst. The use of this receptor by MP may facilitate their subsequent intracellular survival.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525590

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  The Abl and Arg kinases mediate distinct modes of phagocytosis and are required for maximal Leishmania infection.

Authors:  Dawn M Wetzel; Diane McMahon-Pratt; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

2.  Second Jenner international glycoimmunology meeting.

Authors: 
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

Review 3.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 4.  Receptor-mediated phagocytosis of Leishmania: implications for intracellular survival.

Authors:  Norikiyo Ueno; Mary E Wilson
Journal:  Trends Parasitol       Date:  2012-06-21

5.  Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.

Authors:  M T Rimoldi; A J Tenner; D A Bobak; K A Joiner
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

6.  Leishmania pifanoi amastigotes avoid macrophage production of superoxide by inducing heme degradation.

Authors:  Nam-Kha Pham; Jennifer Mouriz; Peter E Kima
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species.

Authors:  Fernanda O Novais; Ba T Nguyen; Daniel P Beiting; Lucas P Carvalho; Nelson D Glennie; Sara Passos; Edgar M Carvalho; Phillip Scott
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

Review 8.  Macrophage receptors for Mycobacterium tuberculosis.

Authors:  J D Ernst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

9.  Tumor suppressor p53 induces apoptosis of host lymphocytes experimentally infected by Leishmania major, by activation of Bax and caspase-3: a possible survival mechanism for the parasite.

Authors:  Mozhgan Moshrefi; Adel Spotin; Hossein Samadi Kafil; Mahmoud Mahami-Oskouei; Behzad Baradaran; Ehsan Ahmadpour; Behzad Mansoori
Journal:  Parasitol Res       Date:  2017-05-30       Impact factor: 2.289

10.  Lipophosphoglycan blocks attachment of Leishmania major amastigotes to macrophages.

Authors:  M Kelleher; S F Moody; P Mirabile; A H Osborn; A Bacic; E Handman
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.